Pharmaceutical composition for inhibiting gastric cancer cell proliferation
By regulating the CDK1, CDK6, and SMAD6 genes, drugs developed using components such as apigenin have solved the problems of toxic side effects and multidrug resistance in the treatment of gastric cancer, achieving effective inhibition of the proliferation of gastric cancer cells and providing a new treatment option.
Patent Information
- Application Number
- CN202410783002.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-18
- Publication Date
- 2024-11-15
AI Technical Summary
Current drug treatments for gastric cancer face challenges such as nonspecific toxicity and multidrug resistance, lack highly effective and low-toxicity chemotherapy drugs, and the regulatory mechanisms for gastric cancer cell proliferation are unclear.
Using apigenin, atractylodes lactone III, rhein, rutin, ellagic acid, quercetin, limonene, typhain, berberine, ginsenoside F2, and kaempferol-3-o-rutin as active ingredients, this study aims to inhibit the proliferation of gastric cancer cells by regulating CDK1, CDK6, and SMAD6 genes, thereby developing a new drug for the treatment of gastric cancer.
It effectively inhibits the proliferation of gastric cancer cells, provides a new potential drug option for the treatment of gastric cancer, reduces the risk of toxic side effects, and enhances the therapeutic effect on gastric cancer.
Smart Images

Figure CN118948831A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of pharmaceutical preparations, and in particular relates to a composition for preparing a drug for inhibiting the proliferation of gastric cancer cells by regulating CDK1, CDK6 and SMAD6 genes. Background Art
[0002] It is reported that the annual incidence of gastric cancer (GC) ranks fourth or fifth in the world, and the annual mortality rate ranks second among all tumors. Although there have been great advances in the diagnosis and treatment of gastric cancer in recent years, its 5-year survival rate is still very low. As a highly malignant tumor, GC has the characteristics of unlimited cell proliferation, invasion, and metastasis, and is a tumor disease with a poor prognosis. It is of great significance to pay attention to and attach importance to the treatment and research of gastric cancer. At present, drug treatment of tumors such as gastric cancer faces two major problems, namely non-specific toxic and side effects and multidrug resistance, which makes it very important to find highly effective and low-toxic chemotherapy drugs. At present, extracting effective anticancer drugs from traditional Chinese medicine has become a hot spot in the research of tumor drug treatment and has made great progress.
[0003] Studies have shown that the occurrence and development of GC is a complex process. The occurrence of most gastric cancers follows the gastric cancer occurrence model proposed by the Correa cascade reaction: normal gastric mucosa-superficial gastritis-atrophic gastritis-small intestinal metaplasia-large intestinal metaplasia-dysplasia (moderate to severe)-gastric cancer. The occurrence of gastric cancer is a multi-gene, multi-step, and multi-stage development process. Under normal circumstances, cell proliferation and apoptosis maintain a dynamic balance. If the balance is disrupted, it will lead to the occurrence of various diseases. Studies have reported that the occurrence of GC is mainly the result of the disruption of the balance between proliferation and apoptosis of gastric mucosal epithelial cells. Cell survival or death depends on the balance between survival and apoptosis signals, and the maintenance of this balance involves multiple molecules and genes.
[0004] In order to explore the specific molecular regulatory mechanism of drugs for treating gastric cancer, researchers have conducted targeted studies on biological processes such as cell cycle, proliferation, apoptosis, differentiation, and DNA damage repair in cells. Studies have shown that tumor suppressor genes mainly play an anti-cancer role by inhibiting the proliferation of gastric cancer cells. Studies have shown that CDK1 (cyclin-dependent kinase 1) is an important regulator of G2-M phase excess. It is reported that CDK1 can cooperate with cyclin B to promote cells to enter the meiotic period. CDK1 is upregulated in CRC circulating tumor cells. CDK1 plays a key role in promoting G2-M phase transition, regulating G1 process, and G1 phase to S phase transition. Studies have shown that increased CDK1 expression levels are closely related to cancer cell proliferation or poor cancer prognosis, and high CDK1 expression rates indicate that CRC patients have a poor prognosis. Therefore, molecules related to cell cycle regulation, including CDKs, have become a research hotspot and are considered to be potential prognostic and therapeutic markers in a variety of cancers. Changes in the expression of CDKs in cells often lead to abnormal cell proliferation and dysfunction of related genes or proteins. By upregulating CDK-related inhibitors, CDK expression is downregulated, further inducing cell cycle arrest in the G1 phase. In addition, the SMAD6 gene has been found to be an important regulatory factor in a variety of human cancers. It has been reported that SMAD6 is upregulated in RB tissues and cells, and SMAD6 downregulation significantly inhibits the proliferation of RB cells. SMAD6 downregulation not only inhibits cell migration, but also delays the EMT process.
[0005] Therefore, it is of positive significance to develop new drugs for the treatment of gastric cancer based on the related genes such as CDK1, CDK6 and SMAD6 that regulate the tumor suppressor function from the aspect of inhibiting the proliferation of gastric cancer cells as direct or indirect regulatory target genes of drugs for the treatment of gastric cancer. Summary of the invention
[0006] To this end, the technical problem to be solved by the present invention is to provide a composition for preparing a drug for inhibiting the proliferation of gastric cancer cells based on regulating CDK1, CDK6 and SMAD6 genes, and then develop more new drug preparations with potential for treating gastric cancer.
[0007] The second technical problem to be solved by the present invention is to provide a pharmaceutical preparation that can regulate CDK1, CDK6 and SMAD6 genes to inhibit the proliferation of gastric cancer cells.
[0008] In order to solve the above technical problems, a composition described in the present invention is used for preparing a drug for inhibiting the proliferation of gastric cancer cells based on regulating CDKs and SMAD6 genes, and the active ingredients of the drug include at least one of apigenin, atractylodes lactone III, chrysophanol, rutin, ellagic acid, quercetin, limonin, typhanoside, berberine, ginsenoside F2, and kaempferol-3-o-rutinoside.
[0009] Specifically, the CDKs genes include CDK1 and CDK2.
[0010] The present invention also discloses a drug for inhibiting the proliferation of gastric cancer cells based on regulating CDKs and SMAD6 genes, wherein the effective ingredients of the drug include at least one of apigenin, atractylodes lactone III, chrysophanol, rutin, ellagic acid, quercetin, limonin, typhanoside, berberine, ginsenoside F2, and kaempferol-3-o-rutinoside.
[0011] The present invention also discloses a medicine for treating gastric cancer, wherein the effective ingredients of the medicine include at least one of apigenin, atractylodes lactone III, chrysophanol, rutin, ellagic acid, quercetin, limonin, typhanoside, berberine, ginsenoside F2 and kaempferol-3-o-rutinoside.
[0012] The present invention also discloses a use of Morodan for preparing a pharmaceutical preparation for treating gastric cancer by regulating CDKs and SMAD6 genes to inhibit the proliferation of gastric cancer cells.
[0013] Based on the fingerprint analysis of the Chinese patent medicine Morodan, the present invention preliminarily determined several drug components in Morodan and their possible regulated target genes; from the genes whose expression levels changed significantly in the transcriptome analysis data, genes related to cell proliferation and tumor suppression such as CDK1, CDK6 and SMAD6 were selected as direct or indirect regulated target genes of Morodan, and then high-throughput transcript analysis (RNAseq) was further performed through Morodan cytological experiments to further clarify the target points of the effective substances in Morodan, and finally verified by fluorescence quantitative (qRT-PCR) method. The effective substances in Morodan that have the function of inhibiting gastric cancer were identified, and the effective ingredients including apigenin, atractylodes lactone III, chrysophanol, rutin, ellagic acid, quercetin, limonin, typhalloidin, berberine, ginsenoside F2, and kaempferol-3-o-rutinoside were screened out. Further cytological experiments were carried out in the gastric epithelial cell system to clarify the effective ingredients of Morodan that can inhibit gastric cancer from the component level. In vitro verification experiments showed that this group of substances can inhibit cell proliferation-related indicators such as CDK1, CDK6 and SMAD6 of gastric cancer cells, providing theoretical support for the development of new drugs for the treatment of gastric cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] In order to make the content of the present invention more clearly understood, the present invention is further described in detail below according to specific embodiments of the present invention in conjunction with the accompanying drawings, wherein:
[0015] Figure 1 This is the quantitative detection result of the active ingredient of Morodan on the tumor suppressor target gene CDK1;
[0016] Figure 2 This is the quantitative detection result of the active ingredient of Morodan on the tumor suppressor target gene CDK6;
[0017] Figure 3 This is the quantitative detection result of the active ingredient of Morodan on the tumor suppressor target gene SMAD6; DETAILED DESCRIPTION
[0018] Example 1
[0019] Morodan is a pure Chinese medicine preparation composed of 18 medicinal materials including lily, Poria, Scrophularia, Lindera strychnifolia, Alisma, Radix Ophiopogonis, Angelica, Atractylodes, Capillaris, White Peony, Dendrobium, Acorus, Rhizoma Chuanxiong, Panax Notoginseng, Radix Sanguisorbae, Rhizoma Corydalis, Pollen Typhae, Gallus Gallus Ternifolia, etc. It has the functions of harmonizing the stomach and spleen, promoting blood circulation and relieving pain, strengthening the spleen and relieving swelling, and can significantly reduce the expression of EGF and EGFR in CAG patients, with good clinical practical effects. Morodan was recommended as the first choice for the treatment of chronic gastritis and chronic atrophic gastritis by the Consensus on Chronic Gastritis in China (2017) formulated by the Gastroenterology Branch of the Chinese Medical Association and the Consensus on Diagnosis and Treatment of Chronic Gastritis by Chinese Medicine Experts (2017) issued by the Chinese Association of Traditional Chinese Medicine.
[0020] In order to explore the problem of effective anti-gastric cancer ingredients in Morodan, the present invention preliminarily determined several drug components in Morodan and their possible regulated target genes through literature research and Morodan fingerprint analysis; then further explored Morodan cytological experiments and carried out high-throughput transcript analysis (RNAseq), further clarified the targets of the effective substances in Morodan, and finally verified the effective substances with anti-gastric cancer function in Morodan through the fluorescence quantitative (qRT-PCR) method.
[0021] In order to explore the specific molecular regulatory mechanism of Moruodan in suppressing cancer, this example performs transcriptome analysis on gastric epithelial cells treated with Moruodan. The analysis results show that Moruodan mainly affects biological processes such as cell cycle, proliferation, apoptosis, differentiation, and DNA damage repair in cells. The present invention further selects CDK1, CDK6, and SMAD6, which are related genes that suppress cancer from the aspect of inhibiting cell proliferation, from the genes whose expression levels change significantly in the transcriptome analysis data as direct or indirect regulatory target genes of Moruodan, preliminarily screens out candidate effective ingredients in Moruodan, and identifies the drug ingredients in Moruodan that can effectively suppress cancer through cytological and molecular experimental verification.
[0022] Establishment of fingerprint of Moruodan and identification of natural medicinal components contained in Moruodan
[0023] By using the metabolomics analysis method, the present invention has identified the effective natural medicinal components contained in Moruodan in the early stage, and successfully identified 220 compound components through database comparison, which is consistent with the results of literature mining. Some of the compound components are shown in Table 1 below.
[0024] Table 1 Components of Morodan Compounds (Part)
[0025]
[0026]
[0027] Enrichment analysis of biological functions regulated by medicinal components in Moluodan
[0028] Morodan was applied to the culture medium of gastric epithelial cells, and the cells were collected and analyzed for transcriptome after 24 hours of treatment. Through enrichment analysis, the biological functions mainly affected by Morodan and the functions of target genes regulated were identified. By analyzing the relevant regulatory factors reported in the literature, the drug components in the Morodan fingerprint were further identified, and the effective components in Morodan that regulate tumor suppression were further accurately identified.
[0029] Combined with the reports on the efficacy of natural compounds in the literature, and comprehensive consideration of drug purchase, application and other issues. In this example, 25 compounds were screened from the Morodan fingerprint library and subjected to cytological experiments (see Table 2 below). The concentrations of various compounds in cytological experiments were determined by reference to literature reports or IC50 determination.
[0030] Table 2 Potentially effective components of Morodan
[0031]
[0032]
[0033] Fluorescence quantitative verification of effective anticancer substances in Morodan
[0034] By analyzing the results of transcriptome analysis, target genes related to tumor suppression in Morodan were screened out. By designing specific primers corresponding to each target gene, the cell transcripts treated with the predicted effective components in Morodan were quantitatively detected. In this embodiment, the various effective components predicted in Morodan were subjected to cell apoptosis detection experiments and literature mining to obtain the appropriate treatment concentration of each predicted component.
[0035] The predicted effective components were dissolved in DMSO and applied to the culture medium of SGC-7901 cells cultured on a 6-well plate, and the DMSO-treated cells were used as a negative control group. SGC-7901 cells were collected 24 hours after drug treatment and RNA was extracted.
[0036] The steps for RNA extraction are as follows:
[0037] (1) Pour off the cell culture medium, wash once with PBS, add 1 ml of Trizol to each well of the 6-well plate, shake gently until the liquid covers the entire surface, let stand at room temperature, shake every 2 minutes, and then transfer to a 1.5 ml RNase-free EP tube;
[0038] (2) RNA isolation: add 200 μl of chloroform (1 / 5 of the total volume), shake vigorously by hand, and let stand at room temperature;
[0039] (3) Centrifuge at 4°C and 12,000 rpm for 10-15 min (balanced and pre-cooled in the centrifuge). After centrifugation, the system is separated into layers: upper layer: RNA (colorless), middle layer: protein, and lower layer: phenol-chloroform phase;
[0040] (4) Transfer the upper liquid phase to a 1.5 ml RNase-free EP tube (pre-cooled on ice), add 500 μl of isopropanol, shake gently to mix, let stand at room temperature, and centrifuge at 4°C and 12,000 rpm for 10-15 min to obtain a crude RNA precipitate;
[0041] (5) Discard the supernatant, add 1 ml of 75% ethanol, shake vigorously by hand to suspend the precipitate, centrifuge at 2-8°C and 7500 rpm for 5-10 min, and remove the supernatant with a pipette or vacuum pump;
[0042] (6) Place the EP tube upside down in the air for 5-10 minutes (or use a pipette to suck away all the supernatant) to dry the RNA precipitate (do not centrifuge and dry in a vacuum). Be careful not to completely dry the RNA precipitate, as this will greatly reduce its solubility.
[0043] (7) Resuspend the RNA precipitate in RNase-free water, pipette and repeatedly blow several times, let stand at room temperature, measure the concentration and store at -20°C.
[0044] The steps for measuring RNA concentration are as follows: Take 1ul of each sample, use a micro-volume UV spectrophotometer to measure the concentration of each RNA sample, and calculate the total amount of RNA that needs to be reverse transcribed based on the concentration. Use the full-form gold reverse transcription kit for reverse transcription.
[0045] Synthesis of cDNA: Calculate the required volume of the reverse transcription system based on the concentrations of each group obtained in the previous step. We generally quantify that 20uL of the reverse transcription system contains 5mg of total RNA. After configuring the reverse transcription system, place the reverse transcription tube in a metal bath for reverse transcription, set the program to 42℃, 15min, 85℃, 5s, and store at 4℃ after the operation is completed.
[0046] Real Time PCR detection of mRNA expression: Take out the reverse transcribed cDNA and place it on ice, and prepare 20μL real-time quantitative PCR system: 2×QuantiTect SYBR Green PCR Master Mix 10μL, Forward Primer 0.8μL, Reverse Primer 0.8μL, template cDNA 2μL, RNase-free water 6.4μL. The gene sequences are shown in Table 3 below. After the reaction system is configured, the mRNA expression is detected on the CFX96 machine. The reaction program is 95℃, 15s; 60℃, 30s; 72℃, 30s for a total of 40 cycles. After the run is completed, analyze the Ct value and check the melting curve. qRT-PCR quantitative detection of target genes is derived from RNAseq analysis results. These genes are involved in biological processes such as cell proliferation, apoptosis and differentiation, immune response, and inflammatory response.
[0047] Table 3 Primer sequences for qRT-PCR
[0048]
[0049]
[0050] Example 2 Identification of substances with anti-cancer function of Morodan
[0051] In this embodiment, among the genes whose expression levels changed significantly in the transcriptome analysis data, the changes in gene transcripts such as CDK1, CDK6 and SMAD6 were used as marker genes for regulating tumor suppression from the aspect of inhibiting cell proliferation.
[0052] The SGC-7901 cell line (frozen and preserved by our laboratory and purchased from the ATCC cell bank) was used as the drug treatment object. The cells have the characteristics of rapid reproduction and easy culture. The cultured SGC-7901 cells were inoculated on a 6-well plate (50w cells were cultured in each well) and cultured with DMEM (10% FBS) culture medium until all cells adhered to the wall. The above-screened candidate effective components of Morodan were dissolved in DMSO and applied to the SGC-7901 cell culture fluid respectively. After incubation for 24 hours, the treated cells were collected. After extracting RNA according to the treatment steps in the aforementioned Example 1, reverse transcription was performed, and qRT-PCR detection was performed using specific primers for the gene to be detected.
[0053] The quantitative detection results of the above-screened potential effective components of Morodan for CDK1, CDK6 and SMAD6 tumor suppressor target genes are shown in Tables 1-3 respectively.
[0054] The experimental results show that many substances contained in Morodan have regulatory effects on signal molecules related to cell proliferation. For example, apigenin, atractylodes lactone III, chrysophanol, rutin, ellagic acid, quercetin, limonin, typhane glycosides, berberine (berberine), ginsenoside F2, kaempferol-3-o-rutinoside and other components can significantly inhibit the expression of CDK1, CDK6 and SMAD6 after treating cells. It can be seen that the ingredients contained in Morodan can play an anti-cancer role in inhibiting the proliferation of gastric cancer cells and provide a theoretical basis for the development of new potential drugs for the treatment of gastric cancer.
[0055] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.
Claims
1. A pharmaceutical composition for inhibiting the proliferation of gastric cancer cells, characterized in that: The composition comprises at least one of apigenin, atractylodes lactone III, chrysophanol, rutin, ellagic acid, quercetin, limonin, typhanoside, berberine, ginsenoside F2 and kaempferol-3-o-rutinoside.
2. The use according to claim 1, characterized in that Inhibition of gastric cancer cell proliferation based on regulation of CDKs and SMAD6 genes.
3. The CDKs genes include CDK1 and CDK2.
4. A drug for inhibiting the proliferation of gastric cancer cells based on regulating CDKs and SMAD6 genes, characterized in that: The active ingredients of the drug include at least one of apigenin, atractylodes lactone III, chrysophanol, rutin, ellagic acid, quercetin, limonin, typhanoside, berberine, ginsenoside F2, and kaempferol-3-o-rutinoside.
5. A drug for treating gastric cancer, characterized in that: The active ingredients of the drug include at least one of apigenin, atractylodes lactone III, chrysophanol, rutin, ellagic acid, quercetin, limonin, typhanoside, berberine, ginsenoside F2, and kaempferol-3-o-rutinoside.
6. A use of Morodan for preparing a pharmaceutical preparation for treating gastric cancer by regulating CDKs and SMAD6 genes to inhibit the proliferation of gastric cancer cells.
